A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

NCT01472848 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: PF 05212389 or placebo
DRUG: PF 05212389 or placebo
DRUG: PF 05212389 or placebo
DRUG: PF 05212389 or placebo
DRUG: PF 05212389 or placebo
DRUG: PF 05212389 or placebo

Sponsor

Pfizer